Moderna Financial Statements From 2010 to 2026

MRNA Stock  USD 42.55  1.52  3.45%   
Moderna's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Moderna's valuation are provided below:
Gross Profit
-2.4 B
Profit Margin
(1.40)
Market Capitalization
16.6 B
Enterprise Value Revenue
6.603
Revenue
2.2 B
We have found one hundred twenty available fundamental ratios for Moderna, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Moderna last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 37.6 B. The current year's Enterprise Value is expected to grow to about 35.4 B

Moderna Total Revenue

4.74 Billion

Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna's main balance sheet or income statement drivers, such as Interest Expense of 29 M, Selling General Administrative of 1.2 B or Total Revenue of 4.7 B, as well as many indicators such as Price To Sales Ratio of 5.45, Dividend Yield of 4.0E-4 or PTB Ratio of 1.6. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
  
Build AI portfolio with Moderna Stock
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Moderna Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.6 B16.3 B7.2 B
Slightly volatile
Total Current Liabilities2.4 B2.5 B1.7 B
Slightly volatile
Other Liabilities975.7 M929.2 M365.4 M
Slightly volatile
Accounts Payable489 M465.8 M163.7 M
Slightly volatile
Cash1.9 B2.2 B1.3 B
Slightly volatile
Net Receivables898.8 M680.8 M574.7 M
Slightly volatile
Other Current Assets281.1 M419.8 M192.2 M
Slightly volatile
Total Liabilities3.2 B3.7 B2.3 B
Slightly volatile
Deferred Long Term Liabilities1.9 M2.1 M2.3 M
Slightly volatile
Total Current Assets5.9 B9.3 B4.4 B
Slightly volatile
Intangible Assets48.3 M46 M25.8 M
Slightly volatile
Other Current Liabilities1.9 B1.8 B672.4 M
Slightly volatile
Common Stock Shares Outstanding354.1 M441.6 M254.1 M
Slightly volatile
Short and Long Term Debt Total576.1 M859 M375 M
Slightly volatile
Property Plant And Equipment Net3.6 B3.4 BB
Slightly volatile
Current Deferred Revenue167.2 M175.9 M838 M
Slightly volatile
Non Current Assets Total4.6 B6.9 BB
Slightly volatile
Non Currrent Assets Other243.3 M468.1 M163.2 M
Slightly volatile
Other Assets1.6 B2.2 BB
Slightly volatile
Long Term Debt15.5 M18 M14.5 M
Slightly volatile
Cash And Short Term Investments5.6 B8.1 B3.9 B
Slightly volatile
Short Term Investments3.3 B5.9 B2.5 B
Slightly volatile
Long Term Debt Total27.6 M44.5 M25.9 M
Slightly volatile
Liabilities And Stockholders Equity11.8 B16.3 B7.8 B
Slightly volatile
Non Current Liabilities Total898.1 M1.2 B700.7 M
Slightly volatile
Capital Surpluse2.4 B1.3 B1.3 B
Slightly volatile
Capital Lease Obligations526.9 M859 M339.5 M
Slightly volatile
Other Stockholder Equity1.8 B995.9 MB
Slightly volatile
Long Term Investments2.9 B2.9 B1.8 B
Slightly volatile
Short and Long Term Debt1.4 M2.2 M1.4 M
Slightly volatile
Preferred Stock Total Equity941.3 M1.1 B1.2 B
Slightly volatile
Non Current Liabilities Other39.3 M41.4 M135.3 M
Slightly volatile
Short Term Debt40.4 M42.5 M57.5 M
Slightly volatile
Property Plant Equipment2.6 B2.5 B849.2 M
Slightly volatile
Common Stock Total Equity31.1 K46 K23.1 K
Slightly volatile
Property Plant And Equipment Gross4.2 BB1.2 B
Slightly volatile
Net Working Capital4.6 B6.8 B2.9 B
Slightly volatile

Moderna Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative1.2 B1.2 B406.3 M
Slightly volatile
Other Operating Expenses8.6 B8.2 B3.1 B
Slightly volatile
Research Development5.5 B5.2 B1.7 B
Slightly volatile
Net Interest Income484.2 M461.1 M123.3 M
Slightly volatile
Interest Income513.2 M488.8 M131.4 M
Slightly volatile
Depreciation And Amortization184.9 M217.3 M118 M
Slightly volatile
Reconciled Depreciation189.2 M217.3 M113.3 M
Slightly volatile
Preferred Stock And Other Adjustments13.7 M15.4 M16.8 M
Slightly volatile
Selling And Marketing Expenses172.7 M167.9 M133.2 M
Slightly volatile

Moderna Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation151.3 M217.3 M110.7 M
Slightly volatile
End Period Cash Flow2.1 B2.2 B1.4 B
Slightly volatile
Stock Based Compensation518 M493.4 M157.4 M
Slightly volatile
Begin Period Cash Flow2.1 B3.4 B1.4 B
Slightly volatile
Dividends Paid326 M310.5 M88.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.455.7419.7906
Very volatile
Dividend Yield4.0E-42.0E-44.0E-4
Slightly volatile
PTB Ratio1.61.683.7568
Pretty Stable
Days Sales Outstanding13977.68101
Pretty Stable
Book Value Per Share15.8225.5517.5404
Slightly volatile
Stock Based Compensation To Revenue0.150.13410.308
Slightly volatile
Capex To Depreciation5.265.02.5602
Slightly volatile
PB Ratio1.61.683.7568
Pretty Stable
EV To Sales5.055.3218.9556
Very volatile
Inventory Turnover7.0611.264.1623
Slightly volatile
Days Of Inventory On Hand31.8733.55305
Slightly volatile
Payables Turnover3.673.253.0261
Slightly volatile
Sales General And Administrative To Revenue0.620.370.483
Pretty Stable
Research And Ddevelopement To Revenue2.481.632.3276
Pretty Stable
Capex To Revenue0.30.380.292
Pretty Stable
Cash Per Share11.6616.4615.1946
Pretty Stable
Days Payables Outstanding110116369
Slightly volatile
Intangibles To Total Assets0.00470.00590.0053
Slightly volatile
Current Ratio4.734.225.1593
Slightly volatile
Tangible Book Value Per Share15.7825.3317.4962
Slightly volatile
Receivables Turnover6.626.216.0731
Very volatile
Shareholders Equity Per Share15.8225.5517.5404
Slightly volatile
Debt To Equity0.04910.06170.0443
Slightly volatile
Capex Per Share2.592.460.9251
Slightly volatile
Graham Net Net5.4610.057.2624
Pretty Stable
Revenue Per Share10.947.58.9235
Slightly volatile
Interest Debt Per Share1.091.810.9579
Slightly volatile
Debt To Assets0.0320.04750.029
Slightly volatile
Graham Number169175156
Slightly volatile
Operating Cycle16887.04147
Pretty Stable
Price Book Value Ratio1.61.683.7568
Pretty Stable
Days Of Payables Outstanding110116369
Slightly volatile
Ebt Per Ebit1.061.050.9711
Slightly volatile
Company Equity Multiplier1.791.491.6483
Pretty Stable
Total Debt To Capitalization0.04560.05770.0414
Slightly volatile
Debt Equity Ratio0.04910.06170.0443
Slightly volatile
Quick Ratio4.684.165.1245
Slightly volatile
Net Income Per E B T0.780.890.9738
Slightly volatile
Cash Ratio1.161.00.7916
Slightly volatile
Days Of Inventory Outstanding31.8733.55305
Slightly volatile
Days Of Sales Outstanding13977.68101
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.851.210.8582
Slightly volatile
Price To Book Ratio1.61.683.7568
Pretty Stable
Fixed Asset Turnover0.930.972.409
Pretty Stable
Debt Ratio0.0320.04750.029
Slightly volatile
Price Sales Ratio5.455.7419.7906
Very volatile
Asset Turnover0.220.20.2005
Slightly volatile
Price Fair Value1.61.683.7568
Pretty Stable

Moderna Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap37.6 B35.9 B17.6 B
Slightly volatile
Enterprise Value35.4 B33.7 B16.6 B
Slightly volatile

Moderna Fundamental Market Drivers

Forward Price Earnings32.4675
Cash And Short Term InvestmentsB

Moderna Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Moderna Financial Statements

Moderna stakeholders use historical fundamental indicators, such as Moderna's revenue or net income, to determine how well the company is positioned to perform in the future. Although Moderna investors may analyze each financial statement separately, they are all interrelated. For example, changes in Moderna's assets and liabilities are reflected in the revenues and expenses on Moderna's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue175.9 M167.2 M
Total Revenue3.7 B4.7 B
Cost Of Revenue1.7 B1.5 B
Stock Based Compensation To Revenue 0.13  0.15 
Sales General And Administrative To Revenue 0.37  0.62 
Research And Ddevelopement To Revenue 1.63  2.48 
Capex To Revenue 0.38  0.30 
Revenue Per Share 7.50  10.94 
Ebit Per Revenue(1.11)(1.17)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. Expected growth trajectory for Moderna significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Moderna assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.85)
Earnings Share
(8.06)
Revenue Per Share
5.756
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.15)
Understanding Moderna requires distinguishing between market price and book value, where the latter reflects Moderna's accounting equity. The concept of intrinsic value—what Moderna's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Moderna's price substantially above or below its fundamental value.
Understanding that Moderna's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moderna represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Moderna's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.